[Lab] split one vial across VendorInvestigate and PeptideMeter — 98.6% and 93.7%
split one vial across VendorInvestigate and PeptideMeter — 98.6% and 93.7%. I will put the method line and the batch identifier up front because that is what makes this checkable. Hard numbers: 98.6% and 93.7%. Anything softer than that is flagged as an impression. It is a triple agonist at the GLP-1, GIP and…
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Not convinced. You are attributing a week of injection-site soreness to the glucagon arm when the escalation rate alone would explain it.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
a lot of the confident posting here is extrapolation